Pump prime only aprotinin inhibits cardiopulmonary bypass-induced neutrophil CD11b up-regulation

Annals of Thoracic Surgery

Volumn 67, Issue 2, 1999, Pages 392-395

  Alonso, Anselmo ^a   Whitten, Charles W ^a   Hill, Gary E ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; CD11B ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; BLEEDING; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HEART MUSCLE REVASCULARIZATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; INFLAMMATION; NEUTROPHIL; PRIORITY JOURNAL; REPERFUSION INJURY;

AGED; APROTININ; CARDIOPULMONARY BYPASS; CORONARY ARTERY BYPASS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MACROPHAGE-1 ANTIGEN; MALE; MIDDLE AGED; NEUTROPHILS; PREMEDICATION; RISK FACTORS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; UP-REGULATION;

EID: 0032918281     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(98)01132-1     Document Type: Article

References (26)

1. Hall R.I., Smith M.S., Rocker G. The systemic inflammatory response to cardiopulmonary bypass pathophysiological, therapeutic, and pharmacological considerations . Anesth Analg. 85:1997;766-782.
2. Carlos T.M., Harlan J.M. Membrane proteins involved in phagocyte adherence to endothelium. Immunol Rev. 114:1990;5-28.
3. Lo S.K., Van Seventer G.A., Levin S.M., Wright S.D. Two leukocyte receptors (CD11a/CD18 and CD11b/CD18) mediate transient adhesion to endothelium by binding to different ligands. J Immunol. 143:1989;3325-3329.
4. Byrne J.G., Smith W.J., Murphy M.P., Couper G.S., Appleyard R.F., Cohn L.H. Complete prevention of myocardial stunning, contracture, low-reflow, and edema after heart transplantation by blocking neutrophil adhesion molecules during reperfusion. J Thorac Cardiovasc Surg. 104:1992;1589-1596.
5. Gillinov A.M., Redmond J.M., Zehr K.J., et al. Inhibition of neutrophil adhesion during cardiopulmonary bypass. Ann Thorac Surg. 57:1994;126-133.
6. Hill G.E., Alonso A., Spurzem J.R., Stammers A.H., Robbins R.A. Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans. J Thorac Cardiovasc Surg. 110:1995;1658-1662.
7. Lemmer J.H., Dilling E.W., Morton J.R., et al. Aprotinin for primary coronary artery bypass grafting a multicenter trial of three dose regimens . Ann Thorac Surg. 62:1996;1659-1668.
8. Levy J.H., Pifarre R., Schaff H.V., et al. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation. 92:1995;2236-2244.
9. Hayashida N., Isomura T., Sato T., Maruyama H., Kosuga K., Aoyagi S. Effects of minimal-dose aprotinin on coronary artery bypass grafting. J Thorac Cardiovasc Surg. 114:1997;261-269.
10. Boyum A. Isolation of mononuclear cells and granulocytes from human peripheral blood. Scand J Clin Lab Invest. 21:(Suppl 97):1968;77-89.
11. Ledbetter J.A., Herzenberg L.A. Xenogeneic monoclonal antibodies to mouse lymphoid differentiation antigen. Immunol Rev. 57:1979;63-90.
12. Morioka K., Muraoka R., Chiba Y., et al. Leukocyte and platelet depletion with a blood cell separator effects on lung injury after cardiac surgery with cardiopulmonary bypass . J Thorac Cardiovasc Surg. 111:1996;45-54.
13. Wilson I.C., Gardner T.J., DiNatale J.M., Gillinov A.M., Curtis W.E., Cameron D.E. Temporary leukocyte depletion reduces ventricular dysfunction during prolonged postischemic reperfusion. J Thorac Cardiovasc Surg. 106:1993;805-810.
14. Simpson P.J., Todd R.F., Fantone J.C., Mickelson J.K., Griffin J.D., Lucchesi B.R. Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mo1, anti-CD11b) that inhibits leukocyte adhesion. J Clin Invest. 81:1988;624-629.
15. Deng M.C., Dasch B., Erren M., Mollhoff T., Scheld H.H. Impact of left ventricular dysfunction on cytokines, hemodynamics, and outcome in bypass grafting. Ann Thorac Surg. 62:1996;184-190.
16. Whitten C.W., Hill G.E., Ivy R., Greilich P.E., Lipton J.M. Does the duration of cardiopulmonary bypass or aortic cross-clamp, in the absence of blood and/or blood product administration, influence the IL-6 response to cardiac surgery? Anesth Analg. 86:1998;28-33.
17. Stack G., Baril L., Napychank P., Snyder E.L. Cytokine generation in stored, white cell-reduced, and bacterially contaminated units of red cells. Transfusion. 35:1995;199-203.
18. Bazzoni G., Nunez A.B., Mascellani G., Bianchini P., Dejana E., Maschio A.D. Effect of heparin, dermatan sulfate, and related oligo-derivatives on human polymorphonuclear leukocyte functions. J Lab Clin Med. 121:1993;268-275.
19. Levy J.H., Bailey J.M., Salmenpera M. Pharmacokinetics of aprotinin in preoperative cardiac surgical patients. Anesthesiology. 80:1994;1013-1018.
20. Wendel H.P., Heller W., Michel J., et al. Lower cardiac troponin T levels in patients undergoing cardiopulmonary bypass and receiving high-dose aprotinin therapy indicate reduction of perioperative myocardial damage. J Thorac Cardiovasc Surg. 109:1995;1164-1172.
21. Sawa Y., Shimazaki Y., Kadoba K., et al. Attenuation of cardiopulmonary bypass-derived inflammatory reactions reduces myocardial reperfusion injury in cardiac operations. J Thorac Cardiovasc Surg. 111:1996;29-35.
22. Cecena-Seldner F.A., Villarreal J. Effect of the kallikrein inhibitor aprotinin on myocardial ischemia and necrosis in man. Angiology. 31:1980;488-496.
23. McMichan J.C., Rosengarten D.S., Philipp E. Prophylaxis of post-traumatic pulmonary insufficiency by protease-inhibitor therapy with aprotinin. Circ Shock. 9:1982;107-116.
24. Wachtfogel Y.T., Kucich U., Hack C.E., et al. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg. 106:1993;1-10.
25. Sultan I., Sunamori M., Suzuki A. Heart preservation: analysis of cardioprotective infusate characteristics. Membrane stabilization, calcium antagonism, and protease inhibition on myocardial viability: a biochemical, ultrastructural, functional study. J Heart Lung Transplant. 11:1992;607-618.
26. Kim K.U., Kown O.J., Jue D.M. Pro-tumour necrosis factor cleavage enzyme in macrophage membrane/particulate. Immunol. 80:1993;134-139.